MX394840B - Nuevos metodos para el tratamiento de la esclerosis multiple. - Google Patents

Nuevos metodos para el tratamiento de la esclerosis multiple.

Info

Publication number
MX394840B
MX394840B MX2019011547A MX2019011547A MX394840B MX 394840 B MX394840 B MX 394840B MX 2019011547 A MX2019011547 A MX 2019011547A MX 2019011547 A MX2019011547 A MX 2019011547A MX 394840 B MX394840 B MX 394840B
Authority
MX
Mexico
Prior art keywords
treatment
multiple sclerosis
new methods
methods
hydroxycyclohexylamino
Prior art date
Application number
MX2019011547A
Other languages
English (en)
Other versions
MX2019011547A (es
Inventor
Derya Shimshek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019011547A publication Critical patent/MX2019011547A/es
Publication of MX394840B publication Critical patent/MX394840B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos de tratamiento de esclerosis múltiple, esclerosis lateral amiotrófica (ALS) o enfermedad de Alzheimer en un sujeto que lo necesita, mediante la administración de una cantidad eficaz de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida o una de sus sales farmacéuticamente aceptables.
MX2019011547A 2017-03-28 2018-03-26 Nuevos metodos para el tratamiento de la esclerosis multiple. MX394840B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477717P 2017-03-28 2017-03-28
PCT/IB2018/052057 WO2018178852A1 (en) 2017-03-28 2018-03-26 New methods for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
MX2019011547A MX2019011547A (es) 2019-11-28
MX394840B true MX394840B (es) 2025-03-24

Family

ID=62002180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011547A MX394840B (es) 2017-03-28 2018-03-26 Nuevos metodos para el tratamiento de la esclerosis multiple.

Country Status (13)

Country Link
US (1) US20200093801A1 (es)
EP (2) EP3600311B1 (es)
JP (2) JP2020515555A (es)
KR (1) KR20190128703A (es)
CN (2) CN116139135A (es)
AU (1) AU2018242535B2 (es)
BR (1) BR112019020093A2 (es)
CA (1) CA3057040A1 (es)
CL (1) CL2019002704A1 (es)
IL (1) IL269681A (es)
MX (1) MX394840B (es)
RU (2) RU2022102195A (es)
WO (1) WO2018178852A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013031A (es) * 2020-04-21 2023-01-04 Novartis Ag Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r.
WO2026164197A1 (en) * 2025-01-30 2026-08-06 Otsuka Pharmaceutical Co., Ltd. Thiadiazole compound as csf1r inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
WO2012151541A1 (en) * 2011-05-05 2012-11-08 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
US20150119267A1 (en) * 2012-04-16 2015-04-30 Sloan-Kettering Institute For Cancer Research Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
WO2015181815A1 (en) * 2014-05-25 2015-12-03 Medwell Laboratories Ltd. Methods for treating multiple sclerosis
JP6851322B2 (ja) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
CN114230571B (zh) * 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EA038531B1 (ru) * 2016-03-25 2021-09-10 Аб Сьянс Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб

Also Published As

Publication number Publication date
MX2019011547A (es) 2019-11-28
CL2019002704A1 (es) 2020-01-10
AU2018242535B2 (en) 2021-01-28
KR20190128703A (ko) 2019-11-18
EP3600311A1 (en) 2020-02-05
CA3057040A1 (en) 2018-10-04
CN110475555A (zh) 2019-11-19
RU2765820C2 (ru) 2022-02-03
AU2018242535A1 (en) 2019-10-03
EP4324523A3 (en) 2024-05-01
JP2023159125A (ja) 2023-10-31
IL269681A (en) 2019-11-28
CN116139135A (zh) 2023-05-23
RU2022102195A (ru) 2022-03-05
EP4324523A2 (en) 2024-02-21
JP2020515555A (ja) 2020-05-28
EP3600311B1 (en) 2024-05-15
US20200093801A1 (en) 2020-03-26
RU2019134182A (ru) 2021-04-28
WO2018178852A1 (en) 2018-10-04
RU2019134182A3 (es) 2021-07-20
BR112019020093A2 (pt) 2020-04-28

Similar Documents

Publication Publication Date Title
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017500493A1 (en) Combination therapy
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
MX387115B (es) Métodos para tratar la influenza.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
PH12015501858B1 (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX380531B (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
MX2017006692A (es) Trastornos neurodegenerativos.
EA201892536A1 (ru) Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2016008968A (es) Compuestos organicos.
MX375924B (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
CO2017004785A2 (es) N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EP4324523A3 (en) New methods for the treatment of multiple sclerosis
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера
EA201891688A1 (ru) Адамантановое производное и его применение
CL2015003679A1 (es) Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico